About: Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
Creator	Malim, Michael Neil, Stuart Tedder, Richard Brown, Matthew Wolf, Jonathan Bowyer, Ruth Spector, Tim Steves, Claire Acors, Sam Capedevilla-Pujol, Joan Couvreur, Simon Dickenson, Ruth Doores, Katie Graham, Carl Hart, Deborah Hemmings, Oliver Kouphou, Neophytos Lista, Maria Maguire, Thomas Martinez Nunez, Rocio Matos, Pedro Mcclure, Myra O'bryne, Aoife Ourselin, Sebastien Poulton, Kate Rosadas, Carolina Scourfield, Edward Seow, Jeffrey Sertkaya, Helin Steel, Kathyrn Wells, Philippa
Source	MedRxiv
abstract	Background: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC
has issue date	2020-07-30(xsd:dateTime)
bibo:doi	10.1101/2020.07.29.20162701
has license	medrxiv
sha1sum (hex)	d32a90101dbf9495b171615b4de3b397ec291394
schema:url	https://doi.org/10.1101/2020.07.29.20162701
resource representing a document's title	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
resource representing a document's body	covid:d32a90101dbf9495b171615b4de3b397ec291394#body_text
is schema:about of	named entity 'Covid-19' named entity 'completed' named entity 'symptoms' named entity 'cohort' named entity 'logging' named entity 'aged' named entity 'individuals' named entity 'symptoms' named entity 'symptom' named entity 'STUDY' named entity 'IGM' named entity 'MAJORITY' named entity 'BACKGROUND' named entity 'LONDON' named entity 'COMPLETED' named entity 'COMPARED' named entity 'HIGHEST' named entity 'COME' named entity 'SOUTH' named entity 'MODELLED' named entity 'SARS-CoV-2' named entity 'Symptom' named entity 'cough' named entity 'core' named entity 'enzyme linked immunosorbent assay' named entity 'Interpretation' named entity 'asymptomatic' named entity 'spike' named entity 'SARS-CoV-2' named entity 'Seroprevalence' named entity 'glycoprotein' named entity 'symptom' named entity 'COVID' named entity 'TwinsUK' named entity 'South-East England' named entity 'SARS-CoV-2' named entity 'London' named entity 'COVID-19 disease' named entity 'population sample' named entity 'asymptomatic' named entity 'Antibody' named entity 'seronegative' named entity 'antibodies' named entity 'COVID' named entity 'seroprevalence' named entity 'seropositive' named entity 'infection' named entity 'gene' named entity 'Central London' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'antibody' named entity 'antibody response' named entity 'algorithm' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software